Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH
This study has been completed.
Sponsor:
Memorial Sloan-Kettering Cancer Center
Information provided by:
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00588536
First received: December 26, 2007
Last updated: June 10, 2009
Last verified: June 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20121019031252im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
The objective of this study is to determine the incidence of complete and partial response and the duration of response in patients with Langerhans Cell Histiocytosis (LCH) treated with sequential administration of oral 6-Thioguanine (6-TG) after Methotrexate (MTX).
Condition | Intervention | Phase |
---|---|---|
Langerhans Cell Histiocytosis |
Drug: Methotrexate Drug: 6-Thioguanine Drug: Leucovorin Calcium |
Phase 2 |
Study Type: | Interventional |
Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With Langerhans Cell in Histiocytosis (LCH) |
Resource links provided by NLM:
Genetics Home Reference related topics:
Langerhans cell histiocytosis
Drug Information available for:
Methotrexate
Thioguanine
Leucovorin Calcium
Methotrexate sodium
Levoleucovorin
U.S. FDA Resources
Further study details as provided by Memorial Sloan-Kettering Cancer Center:
Primary Outcome Measures:
- Determine the incidence of complete and partial response and the duration of response in patients wit hLangerhans Cell Histiocytosis (LCH) treated with sequential administration of oral 6-TG after MTX. [ Time Frame: Conclusion of the study ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Define the toxicity of this sequential drug combination as defined by NCI Common Toxicity Criteria. [ Time Frame: Conclusion of study ] [ Designated as safety issue: Yes ]
Enrollment: | 5 |
Study Start Date: | January 1995 |
Study Completion Date: | June 2009 |
Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: 1
MTX, 6-TG, Leucovorin
|
Drug: Methotrexate
MTX 30mg/m2 (or 1mg/kg for infants) orally, given in three equally divided doses at 0,8, and 16hrs
Other Name: MTX
Drug: 6-Thioguanine
6-TG 300mg/m2 (or 10mg/kg for infants) orally, given in one dose.
Other Name: 6-TG
Drug: Leucovorin Calcium
5mg orally at 36,48, and 60hrs (or 12 hrs after the dose of 6-TG and then every 12 hrs for a total of 3 doses)
|
![](https://webarchive.library.unt.edu/web/20121019031252im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients with histologic proof of LCH who have multifocal or multisystem disease involvement.
- Patients must have a life expectancy of at least 8 weeks.
- All patients must have ECOG performance level rating of-< 2.
- Patients or their parents (guardian) must sign an informed consent indicating that they are aware of the investigational nature of the study, using commercially available drugs.
- Patients must have recovered from the toxic effects of prior therapy before entering this study or at least 2 weeks should have elapsed since the end of last course of chemotherapy.
- Patients must have adequate liver function (bilirubin _< 2.0 mg/dl, SGOT less than 1.5 times normal (unless it is due to disease), adequate renal function (creatinine <_ 1.5 mg/dl, creatinine clearance >_ 60 ml/min/1.73 m2) and normal electrolytes.
- Patients should have a granulocyte count > 500/uL and a platelet count >_ 100,000/uL (unless due to disease involvement of the bone marrow).
- Male and female patients of child-bearing age should use effective methods of contraception, if sexually active.
Exclusion Criteria:
- Patients with active infections or significant medical conditions other than their disease (LCH) shall be excluded.
![](https://webarchive.library.unt.edu/web/20121019031252im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Please refer to this study by its ClinicalTrials.gov identifier: NCT00588536
Locations
United States, New York | |
Memorial Sloan-Kettering Cancer Center | |
New York, New York, United States, 10065 |
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
Investigators
Principal Investigator: | Tanya Trippett, MD | Memorial Sloan-Kettering Cancer Center |
![](https://webarchive.library.unt.edu/web/20121019031252im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Additional Information:
No publications provided
Responsible Party: | Tanya Trippett, MD, Memorial Sloan-Kettering Cancer Center |
ClinicalTrials.gov Identifier: | NCT00588536 History of Changes |
Other Study ID Numbers: | 94-132 |
Study First Received: | December 26, 2007 |
Last Updated: | June 10, 2009 |
Health Authority: | United States: Institutional Review Board |
Keywords provided by Memorial Sloan-Kettering Cancer Center:
Langerhans Cell Histiocytosis LCH 6-Thioguanine 6-TG |
Methotrexate MTX 94-132 |
Additional relevant MeSH terms:
Histiocytosis Histiocytosis, Langerhans-Cell Lymphatic Diseases Lung Diseases, Interstitial Lung Diseases Respiratory Tract Diseases Leucovorin Levoleucovorin Methotrexate Thioguanine Vitamin B Complex Vitamins Micronutrients Growth Substances Physiological Effects of Drugs |
Pharmacologic Actions Antidotes Protective Agents Abortifacient Agents, Nonsteroidal Abortifacient Agents Reproductive Control Agents Therapeutic Uses Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Dermatologic Agents Enzyme Inhibitors Folic Acid Antagonists Immunosuppressive Agents |
ClinicalTrials.gov processed this record on October 17, 2012